AI-generated summary
The authors describe a retrospective case series of two adolescents with persistent PANS/PANDAS symptoms who received home-based transcranial photobiomodulation with a 1070 nm device plus neurofeedback. One participant had a reported 73% reduction in PANS-31 severity and the other a 50% reduction in obsessive-compulsive symptoms. The authors state these are preliminary observations, with no conclusions about efficacy or causality possible.
- Participants
- 2
- Who or what was studied
- Two adolescents with persistent PANS/PANDAS symptoms despite more than 10 years of multidisciplinary care
- Wavelengths
- 1070 nm
- Limits stated in the abstract
- The retrospective design, very small sample, prior and concurrent interventions, and non-uniform assessment schedules preclude conclusions about efficacy, causality, or attribution.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
PANS and PANDAS are neuroimmune conditions characterized by neuropsychiatric symptoms, including obsessive-compulsive features, cognitive dysfunction, and emotional dysregulation, that may persist despite multimodal treatment. Adjunctive neuromodulation approaches remain underexplored in this population.
Methods
This retrospective observational case series describes two adolescents with persistent PANS/PANDAS symptoms despite more than 10 years of multidisciplinary care who received home-based transcranial photobiomodulation (tPBM) using a 1070 nm near-infrared device and adjunctive swLORETA neurofeedback as part of routine clinical care. Multimodal outcomes included the PANS 31-Item Symptom Rating Scale, Yale-Brown Obsessive Compulsive Scale, CogniFit CAB-Pro, BrainGauge, caregiver-reported functional outcomes, and qEEG.
Results
Reductions in neuropsychiatric symptom burden and functional gains were observed during the observation windows. One participant showed a 73% reduction in PANS-31 severity with improvements across multiple cognitive domains; the other showed a 50% reduction in obsessive-compulsive symptom severity and progressed from homebound status to full school participation. Changes were observed across clinical, cognitive, functional, and qEEG measures; however, outcome timing differed across participants and instruments.
Conclusion
These findings should be interpreted as preliminary, hypothesis-generating observations only. Because of the retrospective design, very small sample size, prior and concurrent interventions, and non-uniform assessment schedules, no conclusions regarding efficacy, causality, or attribution to either intervention or their combined use can be drawn. Prospective controlled studies are needed to evaluate efficacy, optimal sequencing, and intervention parameters.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1070 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Neurofeedback, Neuromodulation, Near-infrared, Sample size. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.